Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidative CD19 CAR T Cells After Allo-HSCT for B-cell Malignancies
NCT04556266Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Vadacabtagene leraleucel in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (4 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 24 months. Planned start Jul 2021; status: withdrawn.
02
Drugs
Vadacabtagene leraleucel
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04556266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556266.